Consideration in Hemophilia Therapy Selection

Seminars in Hematology

Volumn 43, Issue SUPPL. 3, 2006, Pages

  Pipe, Steven ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLOOD TRANSFUSION; COST BENEFIT ANALYSIS; CRYOPRECIPITATE; DECISION MAKING; DISEASE TRANSMISSION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; INFECTION; NUCLEIC ACID AMPLIFICATION; PARVOVIRUS; PRION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REIMBURSEMENT; SARS CORONAVIRUS; SCREENING; SCREENING TEST; SEROLOGY; TREATMENT PLANNING; VIRAL CONTAMINATION; VIRUS DETECTION; VIRUS INACTIVATION; VON WILLEBRAND DISEASE; WEST NILE FLAVIVIRUS;

BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASES; CONSUMER PRODUCT SAFETY; DISEASE TRANSMISSION, HORIZONTAL; HEMOPHILIA A; HUMANS; PUBLIC HEALTH; QUALITY OF HEALTH CARE; RECOMBINANT PROTEINS; RISK; SOCIAL RESPONSIBILITY;

EID: 33646024001     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.02.002     Document Type: Article

References (41)

1. Hilgartner M.W. The need for recombinant factor VIII. Historical background and rationale. Semin Hematol 28 suppl 1 (1991) 6-9
2. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program, 6 (No. 2) (2004). http://www.cdc.gov/ncbddd/hbd/documents/UDC6(2).pdf Available at http://www.cdc.gov/ncbddd/hbd/documents/UDC6(2).pdf, accessed November 2005
3. Mauser-Bunschoten E.P., Roosendaal G., and van den Berg H.M. Product choice and haemophilia treatment in the Netherlands. Haemophilia 7 (2001) 96-98
4. Mantovani L.G., Monzini M.S., Mannucci P.M., Scalone L., Villa M., and Gringeri A. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia. A discrete choice experiment. Haemophilia 11 (2005) 589-597
5. Brown S.A., Aledort L.M., and Lee C.A. Issues in making a therapeutic choice. Recombinant and/or human-derived products. Haemophilia 6 (2000) 125-129
6. Aledort L.M. Making a therapeutic choice. Human versus recombinant fractions-Can we do it?. Haemophilia 7 suppl 1 (2001) 1-3
7. Farrugia A. Evolving perspectives in product safety for haemophilia. Haemophilia 8 (2002) 236-243
8. Miller R. The responsibility of separating truth from myth to patient and family. Haemophilia 7 (2001) 91-95
9. Magli-Barioz D., Ounnoughene N., Paugy P., Quarre M.C., Vassilief D., Lopez I., et al. Evaluation of the impact of information about treatment-related risks in patients receiving blood-derived or recombinant medications. Haemophilia 10 (2004) 572-581
10. Giangrande P.L. Treatment of hemophilia: Recombinant factors only? Yes. J Thromb Haemost 1 (2003) 214-215
11. Kasper C.K. Concentrate safety and efficacy. Haemophilia 8 (2002) 161-165
12. AABB: All About Blood. Available at: http://www.aabb.org/All_About_Blood/FAQs/aabb_faqs.htm, accessed December 2005
13. Giachetti C., Linnen J.M., Kolk D.P., Dockter J., Gillotte-Taylor K., Park M., et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 40 (2002) 2408-2419
14. Food and Drug Administration. Guidance for Industry. Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of HIV-1 and HCV (2004), US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, MD
15. Centers for Disease Control and Prevention. Update. West Nile Virus screening of blood donations and transfusion-associated transmission-United States, 2003. MMWR Morb Mortal Wkly Rep 53 (2004) 281-284
16. Rajcani J. Molecular mechanisms of virus spread and virion components as tools of virulence. A review. Acta Microbiol Immunol Hung 50 (2003) 407-431
17. Klempner M.S., and Shapiro D.S. Crossing the species barrier-One small step to man, one giant leap to mankind. N Engl J Med 350 (2004) 1171-1172
18. Chandran K., Farsetta D.L., and Nibert M.L. Strategy for nonenveloped virus entry. A hydrophobic conformer of the reovirus membrane penetration protein micro 1 mediates membrane disruption. J Virol 76 (2002) 9920-9933
19. Knight R.S., and Will R.G. Prion diseases. J Neurol Neurosurg Psychiatry 75 suppl 1 (2004) i36-i42
20. Jakubik J.J., Vicik S.M., Tannatt M.M., and Kelley B.D. West Nile virus inactivation by the solvent/detergent steps of the second and third generation manufacturing processes for B-domain deleted recombinant factor VIII. Haemophilia 10 (2004) 69-74
21. Goodnough L.T. Risks of blood transfusion. Crit Care Med 31 suppl 12 (2003) 678-686
22. Miekka S.I., Busby T.F., Reid B., Pollock R., Ralston A., and Drohan W.N. New methods for inactivation of lipid-enveloped and non-enveloped viruses. Haemophilia 4 (1998) 402-408
23. Yokoyama T., Murai K., Murozuka T., Wakisaka A., Tanifuji M., Fujii N., et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang 86 (2004) 225-229
24. Soucie J.M., Richardson L.C., Evatt B.L., Linden J.V., Ewenstein B.M., Stein S.F., et al. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. Transfusion 41 (2001) 338-343
25. Chambost H., and Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 11 (2005) 92-99
26. Giangrande P. Haemophilia B. Christmas disease. Expert Opin Pharmacother 6 (2005) 1517-1524
27. Giles A.R., Rivard G.E., Teitel J., and Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 19 (1998) 139-148
28. National Hemophilia Foundation. MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders (2003). http://www.hemophilia.org/research/masac/masac151.pdf MASAC Document #151, Nov. Available at: www.hemophilia.org/research/masac/masac151.pdf, accessed July 2004
29. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9 (2003) 1-23
30. Association of Hemophilia Clinic Directors of Canada. Clinical Practice Guidelines. Hemophilia and von Willebrand's Disease (1999). http://www.ahcdc.ca/Management.htm (2. Management; Update 2). July 7. Available at http://www.ahcdc.ca/Management.htm, accessed December 2005
31. Abshire T.C., Brackmann H.H., Scharrer I., Hoots K., Gazengel C., Powell J.S., et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy-International Kogenate-FS Study Group. Thromb Haemost 83 (2000) 811-816
32. Mitterer A., Mundt W., Bjornson E., and Dorner F. Development of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM). J Thromb Haemost 1 suppl 1 (2003) P1652 (abstr)
33. Lusher J.M. First and second generation recombinant factor VIII concentrates in previously untreated patients. Recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost 28 (2002) 273-276
34. Gringeri A., Tagliaferri A., Tagariello G., Morfini M., Santagostino E., Mannucci P., and ReFacto-AICE Study Group. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 126 (2004) 398-404
35. Lusher J.M. Hemophilia treatment. Factor VIII inhibitors with recombinant products: Prospective clinical trials. Haematologica 85 suppl 10 (2000) 2-5
36. Mauser-Bunschoten E.P., van der Bom J.G., Bongers M., Twijnstra M., Roosendaal G., Fischer K., et al. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. Haemophilia 7 (2001) 364-368
37. Scharrer I., Bray G.L., and Neutzling O. Incidence of inhibitors in haemophilia A patients-A review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5 (1999) 145-154
38. Mannucci P.M., Schimpf K., Abe T., Aledort L.M., Anderle K., Brettler D.B., et al., International Investigator Group. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. Transfusion 32 (1992) 134-138
39. Ironside J.W. The spectrum of safety. Variant Creutzfeldt-Jakob disease in the United Kingdom. Semin Hematol 40 (2003) 16-22
40. Ironside J.W., and Head M.W. Variant Creutzfeldt-Jakob disease. Risk of transmission by blood and blood products. Haemophilia 10 suppl 4 (2004) 64-69
41. Dunstan R.A., and Alpers M.P. Variant Creutzfeldt-Jakob disease. implications for the health care system. Aust NZ J Public Health 29 (2005) 308-312